Zai Lab Agrees to $250 Million ADS Placement for Drug Development

The Nasdaq-listed drugmaker expects $241.17 million after expenses, primarily to fund global development of zocilurtatug pelitecan.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.